Single-cell Characterization of the Cellular Landscape of Acral Melanoma Identifies Novel Targets for Immunotherapy

• Published in: Clinical cancer research Vol. 28; no. 10; pp. 2131 - 2146
• Main Authors: Li, Jiannong, Smalley, Inna, Chen, Zhihua, Wu, Jheng-Yu, Phadke, Manali S, Teer, Jamie K, Nguyen, Thanh, Karreth, Florian A, Koomen, John M, Sarnaik, Amod A, Zager, Jonathan S, Khushalani, Nikhil I, Tarhini, Ahmad A, Sondak, Vernon K, Rodriguez, Paulo C, Messina, Jane L, Chen, Y Ann, Smalley, Keiran S M
• Format: Journal Article
• Language: English
• Published: United States 13.05.2022
• Subjects: Humans; Immunologic Factors - therapeutic use; Immunotherapy; Melanoma - drug therapy; Melanoma - therapy; Melanoma, Cutaneous Malignant; Neoplasms, Second Primary; Skin - pathology; Skin Neoplasms - drug therapy; Skin Neoplasms - therapy
• ISSN: 1078-0432; 1557-3265
• DOI: 10.1158/1078-0432.ccr-21-3145

Acral melanoma is a rare subtype of melanoma that arises on the non-hair-bearing skin of the palms, soles, and nail beds. In this study, we used single-cell RNA sequencing (scRNA-seq) to map the transcriptional landscape of acral melanoma and identify novel immunotherapeutic targets. We performed scRNA-seq on nine clinical specimens (five primary, four metastases) of acral melanoma. Detailed cell type curation was performed, the immune landscapes were mapped, and key results were validated by analysis of The Cancer Genome Atlas (TCGA) and single-cell datasets. Cell-cell interactions were inferred and compared with those in nonacral cutaneous melanoma. Multiple phenotypic subsets of T cells, natural killer (NK) cells, B cells, macrophages, and dendritic cells with varying levels of activation/exhaustion were identified. A comparison between primary and metastatic acral melanoma identified gene signatures associated with changes in immune responses and metabolism. Acral melanoma was characterized by a lower overall immune infiltrate, fewer effector CD8 T cells and NK cells, and a near-complete absence of γδ T cells compared with nonacral cutaneous melanomas. Immune cells associated with acral melanoma exhibited expression of multiple checkpoints including PD-1, LAG-3, CTLA-4, V-domain immunoglobin suppressor of T cell activation (VISTA), TIGIT, and the Adenosine A2A receptor (ADORA2). VISTA was expressed in 58.3% of myeloid cells and TIGIT was expressed in 22.3% of T/NK cells. Acral melanoma has a suppressed immune environment compared with that of cutaneous melanoma from nonacral skin. Expression of multiple, therapeutically tractable immune checkpoints were observed, offering new options for clinical translation.